RedChip Companies
|
Weekly Newsletter
|
|
Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients
|
Aridis Pharmaceuticals (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the Phase 2a clinical trial of AR-501 in cystic fibrosis (CF) patients. The Company is on track to complete database lock, data analyses, and disclose top-line data in the first quarter of 2023.
For more information, visit www.aridispharma.com
|
Sidus Space Receives NOAA Tier 1 License
Sidus Space (Nasdaq: SIDU), a Space-as-a-Service company focused on mission critical hardware manufacturing combined with commercial satellite design, manufacture, launch, and data collection, has secured U.S. regulatory approval to provide global data services from its upcoming LizzieSat-1 mission through a Tier 1 license granted by the National Oceanographic and Atmospheric Administration (NOAA).
|
BioVie’s Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease Has Fully Enrolled the Targeted 316 Patients
BioVie (Nasdaq: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, announced that it achieved its enrollment target of more than 316 patients in its Phase 3 trial. The Company has opted to continue enrolling up to 400 patients without the pre-specified interim data analysis due to NE3107’s safety in this study to date and a faster than expected pace of study enrollment.
|
|
|
ASP Isotopes Inc. Enters into 25-Year Supply Agreement Valued at Up to $27 Million per Annum for Highly Enriched Molybdenum-100
ASP Isotopes (Nasdaq: ASPI), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries, entered into a 25-year supply agreement for highly enriched Molybdenum-100 (Mo-100) with BRICEM (Beijing Research Institute of Chemical Engineering Metallurgy). Mo-100 is used in the preparation of radiopharmaceuticals used in nuclear medicine procedures to diagnose heart disease and cancer, to study organ structure and function, and to perform other important medical applications. The contract has a value of up to $27 million per annum for 25 years and deliveries are scheduled to commence in July 2023.
|
Nemaura Commences Pilot Program of Miboko with the NHS in the United Kingdom
Nemaura Medical (Nasdaq: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle and weight reduction programs, announced that it has commenced patient studies of its proprietary metabolic health program, Miboko, with the National Health Service (NHS) in the United Kingdom. Miboko, is the first metabolic tracking program to integrate a non-invasive glucose sensor with a lifestyle app that includes recording of food and drink, educational content, and an analytics platform.
|
|
|
Upcoming Events |
|
|
|
NASDAQ: RVSN - Rail Vision |
11:00am Eastern |
Rail Vision is the leading provider of obstacle detection and classification systems in the railway industry. With the Company’s unique cognitive sensor fusion technology, based on advanced electrooptic sensors, artificial intelligence and deep learning, Rail Vision systems detect objects on and along the tracks from a distance of up to two kilometers – in real time – as well as in all weather and light conditions. |
|
|
|
|
NASDAQ : AMAO - Royalty Management Corporation |
4:15pm Eastern |
Royalty Management Corporation is a royalty company building shareholder value to benefit both our shareholders and communities by acquiring and developing high value assets in a sustainable market environment. |
|
|
|
|
NASDAQ : SIDU - Sidus Space Inc. |
4:15pm Eastern |
Sidus Space Inc is a Space-as-a-Service company focused on commercial satellite design, manufacture, launch, and data collection with a vision to enable space flight heritage status for new technologies and deliver data and predictive analytics to both domestic and global customers. |
|
|
|
|
NYSE American: CANF - Can-Fite BioPharma Ltd. |
11:00am Eastern |
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Psoriasis, and liver diseases including advanced liver cancer and NASH. |
|
|
|
|
NASDAQ: NTRB - Nutriband |
4:15pm Eastern |
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies, benefitting patients, physicians, and payers. |
|
|
Archive Events |
|
|
|
OTCQB: ILAL - International Land Alliance |
Meeting Duration 46 minutes |
International Land Alliance (ILAL) is a developer of residential communities in Northern Baja California with projects are targeted at buyers and investors of primary, vacation, and/or retirement homes. |
|
|
|
|
NASDAQ: DPRO - Draganfly |
Meeting Duration 49 minutes |
Draganfly has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. |
|
|
|
|
NASDAQ: UNCY - Unicycive Therapeutics Inc. |
Meeting Duration 51 minutes |
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. |
|
|
|
|
NASDAQ: APM - Aptorum Group |
Meeting Duration 37 minutes |
Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to developing and commercializing therapeutic assets to treat diseases with unmet medical needs. Aptorum's current drug pipeline includes indications in oncological diseases (including orphan oncology indications) and infectious diseases. |
|
|
|
|
NASDAQ: IINN - Inspira Technologies |
Meeting Duration 43 minutes |
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. |
|
|
|
|
NASDAQ: DGLY- Digital Ally Inc. |
Meeting Duration 45 minutes |
Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets. |
|
|
Lesson of the Week
Look for companies with low PE ratios.
|
|
|
RedChip TV |
MidSouth Week in Review
The S&P rose 1% for the week and is up 16% from its October low.
|
|
|
You are receiving this email because your email is subscribed to our mailing list.
Click here to unsubscribe your email address from this list.
Copyright © 2022. All rights reserved.
|
© 2022 RedChip , All rights reserved
|
|
|
|
|
|